Acute Leukemia News

• Targeted Tx Improves Outcomes in High-Risk Pediatric Cancers 'Real-world data' show it is possible to identify precision targets in relapsed pediatric cancers that can guide clinical decision making.
  Medscape Medical News, May 28, 2020
• Alert FDA Approves Olaparib for Certain Metastatic Prostate Cancers Another PARP inhibitor, Lynparza, has been approved for use in prostate cancer.
  FDA Approvals, May 20, 2020
• ACC 2020Universal CAR-T Therapy Produces CRs in Relapsed/Refractory T-ALL A universal chimeric antigen receptor (CAR) T-cell therapy produced responses in adults with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) in initial findings from an ongoing study.
  Medscape Medical News, May 20, 2020
• Alert First PARP Inhibitor Approved for Metastatic Prostate Cancer The FDA has granted rucaparib (Rubraca) an accelerated approval for use in BRCA1/BRCA2 mutation-positive metastatic castration-resistant prostate cancer.
  FDA Approvals, May 19, 2020
• Secondary Acute Lymphoblastic Leukemia More Lethal Than De Novo A new analysis of 8300 patients with ALL undergoing chemotherapy revealed that secondary ALL is common, and the prolonged long-term survival rate is 30% to 50%. Women had a lower risk of death than men.
  Medscape Medical News, May 14, 2020
• Onc Daily: Cancer Drug Costs vs Benefits, AML Cardioprotection These are the most important oncology stories you need to know about today.
  Medscape Medical News, May 13, 2020
• AML: 'Start as Oncology Patients, but Return With Heart Damage' Children treated for acute myeloid leukemia are often cured of their cancer but return years later with hearts damaged by therapy. Cardioprotection with dexrazoxane could help, say experts.
  Medscape Medical News, May 12, 2020
• BSH 2020Rituximab Offers No Extra Benefit to Induction Chemo in ALL Patients with B-precursor acute lymphoblastic lymphoma may not benefit from adding rituximab to standard induction chemotherapy, suggests UK trial data that also identified novel genetic risk factors.
  Medscape News UK, May 08, 2020
• Alert EU Panel OKs Glasdegib for AML and Luspatercept for MDS Glasdegib has been recommended for approval in Europe for acute myeloid leukemia, and luspatercept has been recommended for anemia associated with myelodysplastic syndromes.
  International Approvals, May 01, 2020
• EHA Webinar Addresses Treating AML Patients With COVID-19 A hematologist in Italy shared his personal experience regarding COVID-19 and the care of acute myeloid leukemia (AML) patients during a webinar hosted by the European Hematology Association.
  Medscape Medical News, April 29, 2020
• US Medical Testing, Cancer Screenings Plunge During Coronavirus Outbreak: Data Firm Analysis Routine medical tests critical for detecting and monitoring cancer and other conditions plummeted in the United States since mid-March, as the coronavirus spread and public officials urged residents to stay home, according to a new report by Komodo Health.
  Reuters Health Information, April 28, 2020
• Cancer Care 'Transformed in Space of a Month' Due to Pandemic Some of the changes are for the better and will last long after the crisis is over, say oncologists. The most revolutionary is the deep dive into 'tele-oncology.'
  Medscape Medical News, April 16, 2020
• Life in the 'Cabin': Two Months Fighting COVID-19 in Wuhan
  Medscape Medical News, April 14, 2020
• Alert First Advance in MDS for Decade: Luspatercept for Anemia Luspatercept is now approved for use in the treatment of anemia in patients with myelodysplastic syndromes (MDS).
  FDA Approvals, April 06, 2020
• Three-Drug Combo 'Highly Effective' in Acute Myeloid Leukemia A new combination of old drugs has shown 'unexpectedly' higher response rates in patients with relapsed/refractory acute myeloid leukemia.
  Medscape Medical News, March 31, 2020
• Medical Meetings May Be Forever Changed COVID-19 has caused medical conferences to be canceled this spring. Some regular attendees are expressing relief. Will this disruption lead to lasting changes?
  Medscape Medical News, March 27, 2020
• Chelation Beneficial in Iron-Overloaded Patients at Lower Risk of Myelodysplastic Syndromes Iron chelation therapy (ICT) with deferasirox led to longer event-free survival in iron-overloaded patients at low-to-intermediate risk of myelodysplastic syndrome (MDS) in a phase 2 study.
  Reuters Health Information, March 24, 2020
• Venetoclax and Chemo: A 'Step Forward' for Children With r/r AML Adding the targeted therapy to chemotherapy has shown good results in pediatric patients with relapsed or refractory acute myeloid leukemia.
  Medscape Medical News, March 17, 2020
• How an Antipsychotic Became Widely Used as an Antiemetic All major guidelines now recommend olanzapine for chemotherapy-induced nausea and vomiting, but the drug has never been formally approved for this use. It was launched as an antipsychotic.
  Medscape Medical News, March 06, 2020
• Broken Health: The Medical Crisis That's Aggravating Iraq's Unrest On the walls of Basra children's cancer hospital hang photos of some of the youngsters who've been treated there. Most are smiling. Some of the portraits have a black stripe in the upper left corner. Those are pictures of children who passed away.
  Reuters Health Information, March 02, 2020